On December 8, 2020, Greenwich LifeSciences (NASDAQ: GLSI) share price closed at $5.20 per share. Greenwich LifeSciences published its 5-year breast cancer data from a Phase IIb trial at the San Antonio Breast Cancer Symposium conference on December 9, which showed 0% breast cancer recurrences over 5 years of follow-up. On that day, the company's stock spiked to $158 per share and closed at $57 per share, surging the next day to $128 per share and closing at $72 per share.
The company experienced another spike in share price on March 8, 2021, opening at $23 per share, spiking at $53 per share, and closing at $37 per share. On March 8, Greenwich announced that Dr. Jaye Thompson would be brought on full time to lead the GP2 Phase III trial in the fight against breast cancer.
Greenwich could see a third one when it announces more GP2 data on April 9-10 at the AACR (American Association for Cancer Research) annual meeting, when the company will release the final 5-year immune response results from its Phase IIb trial.
https://finance.yahoo.com/news/greenwich-lifesciences-could-see-another-163143119.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.